G1 Therapeutics is a clinical-stage oncology company developing novel small-molecule therapies that address unmet needs in people with cancer. Its lead programs are CDK4/6 inhibitors G1T28 and G1T38. G1T28 is a potential first-in-class combination therapy currently in two proof-of-concept trials in patients with small-cell lung cancer. G1T38 is described as a potential best-in-class oral drug and was slated to begin clinical development later this month. The company completed a $47M Series C to advance clinical development of these programs and to expand its pipeline across multiple oncology indications. G1 Therapeutics is led by CEO Mark Velleca, MD, PhD, and is based in Research Triangle Park, NC. G1 Therapeutics is a privately held, clinical-stage pharmaceutical company focused on discovering and developing novel small-molecule therapies in oncology. The company leverages a proprietary kinase drug discovery platform to advance a pipeline targeting CDK4/6 antineoplastics and bone marrow chemoprotection. Its lead program, G1T28, is a highly potent and selective CDK4/6 inhibitor currently being evaluated in Phase 1a trials in healthy volunteers. Data from the Phase 1a study will inform dose and schedule for multiple Phase 1b/2a trials in cancer patients planned to begin in 2015. The company intends to use new financing to advance G1T28 through proof of concept as both an antineoplastic agent and a chemoprotectant. G1 Therapeutics is a pharmaceutical company focused on discovering and developing novel small molecules for cancer therapy and biodefense applications. Its lead clinical candidate is a proprietary CDK4/6 inhibitor that has been evaluated in multiple preclinical studies for the treatment of chemotherapy-induced myelosuppression. The company intends to use newly raised capital to advance that candidate through an IND filing and into initial clinical testing. Based on a pre-IND meeting with the FDA, G1 expected to file its IND by summer 2014 and to initiate clinical testing before the end of 2014. G1 was founded by Dr. Ned Sharpless and Dr. Kwok Wong and is led by Executive Chair Christy Shaffer.

Total raised

$93M

Funding rounds

3

Latest round

Series C

Latest activity

May 2016